Myelodysplastic syndromes: Contemporary review and how we treat.
about
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersThe Role of Toll-Like Receptors in Hematopoietic MalignanciesChronic myelomonocytic leukemia mimicking hematologic systemic lupus erythematosus.Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform.Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromesPreclinical modeling of myelodysplastic syndromes.The risk of infections in patients with myelodysplastic syndromes in 2016.Myelodysplastic Syndromes: Updates and Nuances.Palliative and End-of-Life Care in Myelodysplastic Syndromes.Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome.Myelodysplastic syndrome patients present more severe respiratory muscle impairment and reduced forced vital capacity: Is disordered inflammatory signaling the culprit?Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatmentIs bone marrow examination always necessary to establish the diagnosis of myelodysplastic syndromes? A proposed non-invasive diagnostic model.Cancer risk in Korean patients with Behçet's disease: A nationwide population-based study.Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.A novel t(3;9)(q21.2; p24.3) associated with SMARCA2 and ZNF148 genes rearrangement in myelodysplastic syndrome.Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.Interleukin-8 and nuclear factor kappa B are increased and positively correlated in myelodysplastic syndrome.Concurrent STAT3, DNMT3A, and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential.MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report.Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.Molecular dissection of engraftment in a xenograft model of myelodysplastic syndromes.Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine.A case report of a very late response to 5-azacytidine in a patient with lower risk myelodysplastic syndrome: Time to update treatment guidelines for lower risk patients.Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures.Diagnosis and treatment of macrocytic anemias in adults.Thrombocytopenia in Patients with Myelodysplastic Syndromes: Still an Unsolved Problem.Regulatory T Cells and Profile of FOXP3 Isoforms Expression in Peripheral Blood of Patients with Myelodysplastic SyndromesA systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
P2860
Q26743743-23371793-3C7E-4A1B-AE5C-4213BCA5DDCBQ28077740-B6576C1A-6A4E-4B08-97AD-8D55EEC0C464Q33433543-FC2D1EE9-B2EE-4925-A893-0E7502F87082Q33442715-A7791FCF-819B-4609-901E-1D271B086448Q33877952-C83028E6-AFD9-4C9B-9EE5-CC4848213D59Q34048030-A949D2E6-D531-4265-AD0C-5936292F9501Q37685237-31B69609-688A-464E-8EB6-10A56C38CEB2Q38701479-96CF0A84-2624-429F-B02B-E50547E5ED3EQ38813702-572F1A10-E0B5-4307-A5EC-CBB5A533F3F6Q38965973-AB3B8D36-E81B-4D16-BEA0-9E9B4B7B130CQ38972536-FDF39177-07C6-41AD-BE49-069660886C5FQ39217354-4A6DDE87-B399-4F9C-9C49-EE9657C77CE1Q40060791-53361A3F-11BD-4B80-9553-6D037836B83BQ41635255-537A9D17-0C51-47DB-9FA0-4F9BF11719BEQ42837959-7015BEEF-A711-425C-8FFF-DC4E7E392808Q47218367-87B1543A-80E7-412B-9890-83137199FB56Q47234029-87815EC6-6A6C-4953-B294-9B0C79454C0FQ47598339-C65D2717-FE3B-4E48-9D43-7733EDA206F4Q48109687-3CFBDF22-F7FB-4B9D-B842-C01CE263D0D0Q48123200-4C05F980-9599-474E-B2E5-BACC0D65E8DBQ50255248-B24EBBA1-7535-4FF2-B565-8622182F0BC8Q51373787-923E0FA0-15C5-4783-8EE5-85F6A889B94AQ51760643-5D9A1207-2F2D-4D6E-ACF9-51602C01CF88Q52721521-AA7A9640-0AE7-4C67-9965-7FCEA6059A56Q53076496-046FDB98-C799-4CFC-939C-DD5606265BB7Q53820609-C3682B94-04F7-4C70-9D86-95903EE155D2Q54226669-FC7E09A2-4B92-4235-AA81-E74B9E2B341EQ55064219-92E8FB93-D4C6-43E4-AB67-0553509BC7EBQ55551706-B1F3AAE4-85BE-4FD6-9082-09C59AE841CBQ55666053-C2E077B3-BB38-49DD-BC5E-DED76C6D2193Q58574940-4BBC4712-9515-4CF5-B42B-7E9C09A5D637Q58720950-985AB399-CFEC-48F2-82A6-FCE67164783A
P2860
Myelodysplastic syndromes: Contemporary review and how we treat.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Myelodysplastic syndromes: Contemporary review and how we treat.
@ast
Myelodysplastic syndromes: Contemporary review and how we treat.
@en
type
label
Myelodysplastic syndromes: Contemporary review and how we treat.
@ast
Myelodysplastic syndromes: Contemporary review and how we treat.
@en
prefLabel
Myelodysplastic syndromes: Contemporary review and how we treat.
@ast
Myelodysplastic syndromes: Contemporary review and how we treat.
@en
P2860
P356
P1476
Myelodysplastic syndromes: Contemporary review and how we treat.
@en
P2093
Mrinal M Patnaik
Naseema Gangat
P2860
P356
10.1002/AJH.24253
P577
2016-01-01T00:00:00Z